Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673164 | 1.00 | CYP2D6 (0.55) | CYP2D6ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL6321887 | 0.84 | ADRB2 (0.65) | CYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL6321893 | 0.84 | ADRB2 (0.65) | CYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL28162666 | 0.84 | MAPT (0.56) | CYP2D6ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL4655066 | 0.84 | RAB9A (0.50) | CYP2D6ADRB2ADRB1ADRB3MTNR1A | |
| SCHEMBL10334338 | 0.83 | MTNR1A (0.55) | CYP2D6ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL4654986 | 0.83 | TDP1 (0.52) | CYP2D6MTNR1AMTNR1BMAPTATM | |
| SCHEMBL4744800 | 0.82 | CYP2D6 (0.57) | CYP2D6ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL666863 | 0.82 | CYP2D6 (0.57) | CYP2D6ADRB2ADRB1ADRB3LMNA | |
| SCHEMBL6321005 | 0.82 | ADRB2 (0.58) | CYP2D6ADRB2ADRB1ADRB3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616852-B1 | PROCESS FOR PRODUCING BETA-HYDROXYESTER | DAISO CO LTD (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-1113033-B1 | Polyhydroxyalkanoate | CANON KK (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-7256305-B2 | Process for producing β-hydroxyester | DAISO CO., LTD. (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7169598-B2 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20060122419-A1 | Esterification of an epoxide, an alcohol and carbon monoxide in the presence of a cobalt carbonyl compound as catalyst and a cocatalyst of substituted pyridine | DAISO CO., LTD. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1616852-A1 | PROCESS FOR PRODUCING BETA-HYDROXYESTER | DAISO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-20040067576-A1 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6649381-B1 | Biosynthesis of high purity polylactones | CANON KABUSHIKI KAISHA (JP) | 2003-11-18 | — | — | US | disclosed |
| US-20030208029-A1 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2003-11-06 | — | — | US | disclosed |
| US-6586562-B2 | Polylactone with units such as of 3-hydroxy-5-(4-fluorophenyl)valeric acid; biosynthesis of the polylactone by microorganism; Pseudomonas cichorii; P. putida; P. jessenii | CANON KABUSHIKI KAISHA (JP) | 2003-07-01 | — | — | US | disclosed |
| US-20020022253-A1 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-1113033-A2 | Polyhydroxyalkanoate, method for production thereof and microorganisms for use in the same | CANON KABUSHIKI KAISHA (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122419-A1 | Esterification of an epoxide, an alcohol and carbon monoxide in the presence of a cobalt carbonyl compound as catalyst and a cocatalyst of substituted pyridine | CYP2E1, CBR1, ADH1A | CYP2D6 564/4885ADRB2 1702/4885ADRB1 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.